ABT 122

Drug Profile

ABT 122

Alternative Names: ABT-122; Dual variable domain immunoglobulin; Dual Variable Domain–Ig™; DVD–Ig™

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Antirheumatics; Immunoglobulins; Monoclonal antibodies
  • Mechanism of Action Interleukin-17 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Rheumatoid arthritis

Highest Development Phases

  • Phase II Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 11 Nov 2016 Efficacy and adverse events data from a 24-week open label extension trial in Rheumatoid arthritis presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR\ARHP-2016)
  • 11 Nov 2016 Safety, pharmacokinetics and efficacy data from a phase II trial in Psoriatic Arthritis presented at the 80th American College of Rheumatology (ARH-2016) and at the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ARHP-2016)
  • 11 Nov 2016 Adverse events and efficacy data from a phase II trial for Rheumatoid arthritis (Combination therapy, Treatment-experienced) presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP - 2016) (3221474; 3221411)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top